<DOC>
	<DOCNO>NCT01378364</DOCNO>
	<brief_summary>The aim study investigate safety , tolerability pharmacokinetics single rise dos AbGn-168H administer intravenous infusion subcutaneous injection healthy male volunteer .</brief_summary>
	<brief_title>Phase I Study AbGn-168H Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Healthy male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) within normal range , 12lead electrocardiogram ( ECG ) , clinical laboratory test 2 . Body Mass Index ( BMI ) 18.5 29.9 kg/m2 3 . Signed date write informed consent prior admission study accordance GCP local legislation Exclusion criterion : 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance 2 . Any evidence clinically relevant concomitant disease opinion investigator 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Chronic relevant acute infection include hepatitis tuberculosis , positive PPD skin test ( 5 mm great ) screen within previous 3 month 5 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) 6 . Use biologic agent within 12 week prior treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>